Pure Global AI
NCT06350812Not yet recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
PegBio Co., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
PB-119
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
PegBio Co., Ltd.
Timeline & enrollment
Phase
Phase 1/2
Start date
May 30, 2024
End date
Apr 29, 2025
Enrollment
32 participants
Primary outcome

Incidence of Treatment-Emergent Adverse Events

Summary

The trial is conducted in a single-center, randomized, double-blind, placebocontrolled,
 dose-increasing design. To evaluate the safety, tolerability, PK characteristics, efficacy
 and immunogenicity of PB-119 injection in Chinese obese subjects.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06350812
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06350812 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by PegBio Co., Ltd. and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.